UTX is a novel mAb targeting a unique epitope on the CD20 antigen and glyco-engineered for enhanced B cell targeting through antibody-dependent cellular cytotoxicity (ADCC). The greater ADCC potency may offer a benefit over currently available anti-CD20s in terms of lower doses and shorter infusion times.

48 subjects were enrolled in the Phase 2 study. Median B cell depletion of >99% was observed at Week 4 and maintained at Week 48. At Week 48, T1-Gd enhancing lesions decreased from a baseline mean of 3.63 to zero; mean T2 lesion volume decreased 10.6% from baseline; 93% of subjects were relapse free and an ARR of 0.07 was observed. Most common adverse events (AEs) were infusion related reactions (all grade 1-2). No discontinuations due to severe AEs were reported. 37 subjects from the Phase 2 trial enrolled in the OLE. As of October 2018, approximately 30% of patients completed 48 weeks in the OLE. UTX continues to be well tolerated, with no discontinuations due to AEs. At the time of presentation, it is anticipated that additional patient follow-up from the OLE study will be available.